SEC Form 4 · accession 0001225208-18-005098

PFIZER INC · PFE

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — Executive Vice President

Period of report

Feb 28, 2018

Accepted (ET)

Mar 2, 2018 · 3:24 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0000078003

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1	Feb 28, 2018	M	101,872	$27.37	A	207,942	D
Common Stock	Feb 28, 2018	S	1,100	$36.84	D	206,842	D
Common Stock	Feb 28, 2018	S	3,200	$36.85	D	203,642	D
Common Stock	Feb 28, 2018	S	5,400	$36.82	D	198,242	D
Common Stock	Feb 28, 2018	S	17,079	$36.83	D	181,163	D
Common Stock^F2	Feb 28, 2018	F	19,606	$36.31	D	161,557	D
Common Stock^F3,F4	Feb 28, 2018	F	61,836	$35.70	D	99,721	D
Common Stock	holding	—	—		—	11,414	I	By Rule 16b-3 Plan

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Appreciation Rights	$27.37	Feb 28, 2018	M	101,872	D	Feb 28, 2018	Feb 28, 2018	Common Stock	101,872	0	D

F1The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon).
F2The reported transaction constitutes the withholding of shares to satisfy tax obligations and payment of exercise price in connection with the earn-out of stock appreciation rights (including dividend equivalents thereon).
F3The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon).
F4Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used.